Credit Suisse’s Robert Willoughby believes the successful closing of the Rite Aid Corporation RAD in H2:16 could help Walgreens Boots Alliance Inc WBA achieve significant revenue growth, cost savings and cash flow opportunities to drive Walgreens’ stock meaningfully higher.
Willoughby maintains an Outperform rating on Walgreens with a price target of $95.
Deal To Close Successfully
Adding the stock to the Credit Suisse Focus List, the analyst mentioned there was limited downside to the deal not closing as expected “given new and potentially more preferred pharmacy network agreements with the leading PBMs, contributions sooner than expected from the early AmerisourceBergen Corp. ABC warrant exercise, and ongoing capital deployment.”
Benefits And Risks
Willoughby believes Walgreens Boots Alliance stands to benefit in the near term from continuing working capital and cost management opportunities, clarity on the closing of the Rite Aid deal and additional expansion of the company’s payor relationships.
However, there are also potential risks, such as reimbursement challenges, weak trends in front-end sales and the risk of the Rite Aid acquisition failing to close successfully.
“The Rite Aid deal, AmerisourceBergen warrant exercise, and PBM relationships should be additive to EPS and our longer term ROIC view,” Willoughby added.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.